- Home
- ZJYL vs MGNX Comparison
ZJYL vs MGNX Comparison
Compare ZJYL & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZJYL
- MGNX
- Stock Information
- Founded
- ZJYL 2006
- MGNX 2000
- Country
- ZJYL China
- MGNX United States
- Employees
- ZJYL N/A
- MGNX N/A
- Industry
- ZJYL Industrial Specialties
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- ZJYL Consumer Discretionary
- MGNX Health Care
- Exchange
- ZJYL Nasdaq
- MGNX Nasdaq
- Market Cap
- ZJYL 127.4M
- MGNX 125.2M
- IPO Year
- ZJYL 2023
- MGNX 2013
- Fundamental
- Price
- ZJYL $0.72
- MGNX $1.27
- Analyst Decision
- ZJYL
- MGNX Hold
- Analyst Count
- ZJYL 0
- MGNX 10
- Target Price
- ZJYL N/A
- MGNX $6.83
- AVG Volume (30 Days)
- ZJYL 323.3K
- MGNX 691.0K
- Earning Date
- ZJYL 05-03-2025
- MGNX 03-20-2025
- Dividend Yield
- ZJYL N/A
- MGNX N/A
- EPS Growth
- ZJYL 18.46
- MGNX N/A
- EPS
- ZJYL 0.02
- MGNX N/A
- Revenue
- ZJYL $23,502,010.00
- MGNX $149,962,000.00
- Revenue This Year
- ZJYL N/A
- MGNX N/A
- Revenue Next Year
- ZJYL N/A
- MGNX $42.52
- P/E Ratio
- ZJYL $29.90
- MGNX N/A
- Revenue Growth
- ZJYL 18.57
- MGNX 155.26
- 52 Week Low
- ZJYL $0.59
- MGNX $1.17
- 52 Week High
- ZJYL $4.65
- MGNX $19.54
- Technical
- Relative Strength Index (RSI)
- ZJYL 41.94
- MGNX 19.69
- Support Level
- ZJYL $0.66
- MGNX $1.89
- Resistance Level
- ZJYL $0.74
- MGNX $2.24
- Average True Range (ATR)
- ZJYL 0.09
- MGNX 0.17
- MACD
- ZJYL -0.02
- MGNX -0.08
- Stochastic Oscillator
- ZJYL 8.17
- MGNX 7.60
About ZJYL JIN MEDICAL INTERNATIONAL LTD.
Jin Medical International Ltd offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other living aids products to be used by people with disabilities or impaired mobility. The company's products are sold to distributors in both China and overseas markets. Its product offerings comprise Wheelechaire serirs, Bath products, oxygen machines, and nursing products. Geographically, it generates the majority of its revenue from Japan.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).